A theme exploring, together with D. Western Therapeutics Institute, Inc. and Senju Pharmaceutical Co., Ltd., the potential to expand the oncology pipeline into treatments for non-cancer ophthalmic diseases, with a view to maximizing the value of oncology drug compounds. The focus is on expanding the use of oncology compounds into ophthalmology, rather than on a specific ophthalmic drug discovery technology or a single partnership.